Lista de obras -

365 Epigenetic Profiling Reveals a Unique Histone Code in Chordoma

artículo científico publicado en 2016

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

artículo científico publicado en 2015

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors

artículo científico publicado en 2014

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

artículo científico publicado en 2017

ATNT-17 EVALUATION OF THE SAFETY AND BENEFIT OF PHASE I ONCOLOGY TRIALS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

artículo científico publicado en 2015

Activity of Sorafenib against desmoid tumor/deep fibromatosis

artículo científico publicado en 2011

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

artículo científico publicado en 2016

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy

artículo científico publicado en 2017

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

artículo científico publicado en 2016

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

artículo científico publicado en 2017

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

artículo científico publicado en 2015

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

artículo científico publicado en 2013

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.

artículo científico publicado en 2007

Genomic aberrations frequently alter chromatin regulatory genes in chordoma

artículo científico publicado en 2016

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

artículo científico publicado en 2018

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas

artículo científico publicado en 2015

Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need ⬇️

artículo científico publicado el 28 de abril de 2011

Locally Aggressive Connective Tissue Tumors.

artículo científico publicado en 2017

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor ⬇️

artículo científico publicado el 30 de noviembre de 2010

Moving Forward One Notch at a Time ⬇️

artículo científico publicado el 7 de mayo de 2012

Multidisciplinary management of recurrent chordomas

artículo científico publicado en 2013

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

artículo científico publicado en 2017

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials

artículo científico publicado en 2014

Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?"

scientific article published on 08 September 2015

OncoKB: A Precision Oncology Knowledge Base

scientific article published on 16 May 2017

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma

artículo científico publicado en 2015

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

artículo científico publicado en 2008

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

artículo científico publicado en 2017

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

artículo científico publicado en 2016

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

artículo científico publicado en 2015

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

artículo científico publicado en 2013

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

scientific article published on 08 August 2019

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

artículo científico publicado en 2015

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

artículo científico publicado en 2014

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

artículo científico publicado en 2016

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

artículo científico publicado en 2014

Reply to E. Younger et al

artículo científico publicado en 2018

Reply to M. Voskoboynik et al

artículo científico publicado en 2014

Sorafenib for Advanced and Refractory Desmoid Tumors

artículo científico publicado en 2018

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

scientific article published on 19 September 2019

The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials ⬇️

artículo científico publicado el 23 de julio de 2012

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

artículo científico publicado en 2017

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

scientific article published on 11 October 2019

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

artículo científico publicado en 2015

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

artículo científico publicado en 2018

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

artículo científico publicado en 2019

Lista de obras de

365 Epigenetic Profiling Reveals a Unique Histone Code in Chordoma

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

ATNT-17 EVALUATION OF THE SAFETY AND BENEFIT OF PHASE I ONCOLOGY TRIALS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

Activity of Sorafenib against desmoid tumor/deep fibromatosis

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.

Genomic aberrations frequently alter chromatin regulatory genes in chordoma

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas

Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need ⬇️

Locally Aggressive Connective Tissue Tumors.

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor ⬇️

Moving Forward One Notch at a Time ⬇️

Multidisciplinary management of recurrent chordomas

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials

Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?"

OncoKB: A Precision Oncology Knowledge Base

Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

Reply to E. Younger et al

Reply to M. Voskoboynik et al

Sorafenib for Advanced and Refractory Desmoid Tumors

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials ⬇️

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types